Phathom Pharmaceuticals, Inc. (PHAT) Stock Profile — Insider Trades & Financials

Revenue$57.6M

Net Income-$21.1M

EPS$-3.03

Gross Margin86.7%

Market Cap$930.6M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Steven Basta

CEO & Executive Director

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Founded: 2018
Employees: 371
Headquarters: Florham Park, New Jersey, United States

⚡

Core Efficiency

ROE?

4.83%

ROA?

-8.16%

D/E Ratio?

-1.59

Op. Margin?

-10.29%

📊

Profitability Ratios

Net Margin?

-36.73%

Loading company sections...

Phathom Pharmaceuticals, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness